Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX G versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX G versus NYSTAFORM.
MYCELEX-G vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily for 7 days or 200 mg once daily for 3 days; or 500 mg single dose. Also available as 1% vaginal cream, 1 applicatorful (5 g) intravaginally once daily for 7-14 days.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Biphasic: initial half-life ~30 minutes, terminal half-life ~30 hours; clinical significance: supports once-daily dosing for topical/vaginal formulations.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Primarily hepatic metabolism; about 80-90% of dose excreted as metabolites in feces via biliary excretion, less than 1% unchanged in urine.
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal